Undervalued stocks: Pfizer, Novo Nordisk, PDD Holdings

What happened: Pfizer (PFE), Novo Nordisk (NVO), and PDD Holdings (PDD) have emerged as undervalued stocks in the market. Pfizer's share traded at $25.08 on June 22nd, with trailing and forward P/E ratios of 19.15 and 8.50 respectively. PDD reported a 11% YoY revenue increase in Q1 2026, while analysts view it as one of the most promising long-term stocks. Novo Nordisk's GLP-1 weight-loss drug, Wegovy, has seen significant demand, outpacing expectations. However, PDD missed both top and bottom line estimates in its recent earnings, leading to a stock price drop.

Market impact: The healthcare and e-commerce sectors are affected. Pfizer and Novo Nordisk, both pharmaceutical giants, benefit from strong drug pipelines and demand for their products. PDD, a Chinese e-commerce company, faces challenges due to missed earnings and slowing growth, impacting investor confidence in the broader e-commerce sector.

What to watch next: Pfizer's earnings report on July 26, 2026, will provide insights into its pipeline and revenue growth. Novo Nordisk's earnings on August 3, 2026, will offer updates on Wegovy's performance. For PDD, the upcoming 2026 Singles' Day sales event on November 11 will be a crucial test of its turnaround efforts and consumer demand for its platform.